As the capabilities of machine learning and artificial intelligence improve, rheumatologists have access to more data than ever, which may enable them to better predict which patients will respond to specific treatments, such as tumor necrosis factor inhibitors.
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…
Gout affects more than 9.2 million adults in the U.S. and is the most common form of inflammatory arthritis. This condition and its complications are painful and potentially disabling with varying risk factors. It is characterized by symptoms that are usually sudden, with intense episodes of painful swelling in one or more joints, most often…
The use of guselkumab improved joint and skin symptoms in biologic naive patients with PsA, according to research presented during ACR Convergence 2021.
In a phase 2 study, tigulixostat treatment proved safe for lowering serum uric acid (sUA) levels in patients with gout.
The FDA has approved the use of secukinumab for pediatric patients with enthesitis-related arthritis and psoriatic arthritis, after research showed a longer time to disease flare than placebo.
According to a German study presented during ACR Convergence 2021, treatment persistence with JAK inhibitors is comparable to TNF inhibitors and other bDMARDs among patients with rheumatoid arthritis.
Enabling rheumatology practices to use complex administration codes for biologic drugs is critical for maintaining patient access to essential therapies.
A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (methotrexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study…
In a study, patients with new-onset polymyalgia rheumatica (PMR) who were treated with subcutaneous tocilizumab were more likely to achieve sustained, glucocorticoid-free remission than patients who received placebo.